【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: methanol123 (meoh), 信区: Pharmaceutical
标 题: merck宣布裁员360，主要是R&D
发信站: BBS 未名空间站 (Sun Jul 17 11:40:19 2016, 美东)
感觉主要是小分子部门。
As the center of gravity shifts in the life sciences, Merck is reorganizing
its R&D teams by closing one facility, eliminating about 360 jobs from three
sites, and transferring other employees to a pair of new facilities that
are slated to open on opposite sides of the country.
A spokeswoman for the drug maker, which is headquartered in New Jersey,
confirmed that the planned changes affect drug discovery, preclinical, and
early development work. As a result, the company is closing a facility in
North Wales, Pa., which screens compounds for potential drug development.
At the same time, Merck is cutting jobs in Kenilworth and Rahway, N.J. The
company is not providing specific breakdowns, but the spokeswoman said that
all totaled, less than 10 percent of roughly 3,600 people in early-stage R&D
work at these three locations will lose their jobs. Another way of looking
at it is the jobs to be lost amount to roughly 3 percent of the 11,900 who
work in R&D companywide.
The North Wales, PA site is being closed (the screening operations there are
moving to Kenilworth). New Jersey discovery chemistry (Kenilworth and
Rahway) is being cut by 20%, and Rahway’s med-chem is entirely moving to
Kenilworth over the next few months. Disease area biology in Kenilworth is
shutting down (not sure what the ramifications of that one might be).
